Etiometry Gains FDA Clearance of AI-Based Algorithm that Alerts Risk of Hypercapnia for Neonates in Critical Care

Etiometry’s IVCO2 Index is now available for continuous non-invasive NICU ventilation monitoring for optimal outcomes without additional devices

Etiometry, the leader in clinical decision-support software, announced its IVCO2 Index was cleared by the Food and Drug Administration for use with neonatal ICU patients under 2kg, who are especially vulnerable to the effects of hypercapnia. This is Etiometry’s 9^th FDA clearance and its second this year.

Read More about AiThority Interview: AiThority Interview with Alistair Dent, Chief Strategy Officer at Profusion

“The IVCO2 Index is a first-of-its-kind algorithm that increases the ability to detect hypercapnia risk without needing additional hardware attached to these fragile patients”

Etiometry’s IVCO2 Index is a game changer in critical care, seamlessly integrating multiple data sources to provide an individualized assessment for ventilation-perfusion mismatch and detect the likelihood a patient will have a PaCO2 of greater than 50 mmHg in mechanically ventilated patients. It has been specifically designed to overcome the challenges of existing conventional monitoring, such as arterial blood gas testing and transcutaneous monitoring for tiny premature newborns.

“The IVCO2 Index is a first-of-its-kind algorithm that increases the ability to detect hypercapnia risk without needing additional hardware attached to these fragile patients,” said Dimitar Baronov, CTO of Etiometry. “It allows clinicians to prioritize care for patients who need it most.”

AiThority Interview Insights: How to Get Started with Prompt Engineering in Generative AI Projects

Many NICU patients require ventilatory support and their conditions can change quickly. Vigilant monitoring for hypercapnia is critical for maximizing neurodevelopmental outcomes and preventing complications. Digital monitoring illuminates the patient’s condition between routine blood gas testing, adding another layer of protection to prevent oversights that may lead to poor outcomes.

“Our proprietary algorithm’s accurate and continuous monitoring for hypercapnia will enable the expansion of improved outcomes achieved by Etiometry partners within cardiac ICUs and PICUs into the NICU environment,” said Shane Cooke, CEO of Etiometry.

Etiometry will showcase all of its risk indices and ways the platform helps improve outcomes by informing escalation and de-escalation decision-making at the upcoming World Congress of Pediatric Cardiology and Cardiac Surgery in Washington, D.C. later this month. Etiometry also supported the submission of five abstracts for this event.

 Latest AiThority Interview Insights : AiThority Interview with Gary Kotovets, Chief Data and Analytics Officer at Dun & Bradstreet

 [To share your insights with us, please write to sghosh@martechseries.com]